newsfilter
← Latest News
GlobeNewswire·

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter;